PDSB (PDS Biotechnology) E10: $-11.53 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PDSB PDS Biotechnology Corp PDSB
31 GF Score
Price $0.67
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology E10?

PDS Biotechnology PDSB -2.81% 31 E10 is $-11.53 as of Mar. 2026. GuruFocus rates PDSB with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

PDS Biotechnology's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.130. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-11.53 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-31), PDS Biotechnology's current stock price is $0.6715. PDS Biotechnology's E10 for the quarter that ended in Mar. 2026 was $-11.53. PDS Biotechnology's Shiller PE Ratio of today is .


PDS Biotechnology  (NAS:PDSB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


PDS Biotechnology E10 Related Terms


PDS Biotechnology E10 Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology E10 Chart

PDS Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -15.47 -12.17

PDS Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.77 -14.16 -13.01 -12.17 -11.53

PDSB vs GRCE, HYPD, RNXT: E10 Comparison

For the Biotechnology subindustry, PDS Biotechnology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Shiller PE Ratio falls into.


PDSB
31GF Score
PDS Biotechnology Corp PDSB
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PDS Biotechnology's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.13/330.2130*330.2130
=-0.130

Current CPI (Mar. 2026) = 330.2130.

PDS Biotechnology Quarterly Data

per share eps CPI Adj_EPS
201606 -6.600 241.018 -9.043
201609 -7.400 241.428 -10.121
201612 -6.600 241.432 -9.027
201703 -8.400 243.801 -11.377
201706 -8.800 244.955 -11.863
201709 -7.400 246.819 -9.900
201712 -9.000 246.524 -12.055
201803 -0.240 249.554 -0.318
201806 -0.170 251.989 -0.223
201809 -0.210 252.439 -0.275
201812 -24.707 251.233 -32.474
201903 1.470 254.202 1.910
201906 -0.750 256.143 -0.967
201909 -1.100 256.759 -1.415
201912 -0.840 256.974 -1.079
202003 -0.390 258.115 -0.499
202006 -0.190 257.797 -0.243
202009 -0.210 260.280 -0.266
202012 -0.160 260.474 -0.203
202103 -0.140 264.877 -0.175
202106 -0.030 271.696 -0.036
202109 -0.240 274.310 -0.289
202112 -0.230 278.802 -0.272
202203 -0.320 287.504 -0.368
202206 -0.200 296.311 -0.223
202209 -0.260 296.808 -0.289
202212 -0.670 296.797 -0.745
202303 -0.320 301.836 -0.350
202306 -0.370 305.109 -0.400
202309 -0.350 307.789 -0.375
202312 -0.350 306.746 -0.377
202403 -0.300 312.332 -0.317
202406 -0.230 314.175 -0.242
202409 -0.290 315.301 -0.304
202412 -0.210 315.605 -0.220
202503 -0.210 319.799 -0.217
202506 -0.210 322.561 -0.215
202509 -0.190 324.800 -0.193
202512 -0.140 324.054 -0.143
202603 -0.130 330.213 -0.130

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-11.53 mean?
PDS Biotechnology (PDSB) has a E10 of $-11.53 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on PDS Biotechnology and its competitors.
Is PDS Biotechnology's E10 too high?
PDS Biotechnology's current E10 is $-11.53. Overall, PDS Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's E10 compare to GRCE and HYPD?
PDS Biotechnology's E10 of $-11.53 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on PDS Biotechnology and its competitors. PDS Biotechnology's current E10 is $-11.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (PDSB) has a current E10 of $-11.53. The current E10 is $-11.53. PDS Biotechnology's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For PDS Biotechnology (PDSB), the current E10 is $-11.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PDS Biotechnology Business Description

Other Exchanges EU6:Germany
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
31GF Score

Get the complete analysis for PDSB

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price